Providing an Update on Antisense Oligonucleotides for Inherited Retinal Disease

Time: 10:00 am
day: Day Two


  • Antisense oligonucleotides have so much promise in Ph1/2 clinical trials in LCA10 and Usher’s Syndrome
  • Recent interim analyses in key trails have shed much light on mechanism of action of antisense oligonucleotides
  • Overview of the data available from clinical trials
  • Clinical trial endpoints for inherited retinal diseases